cx-4945 and Triple-Negative-Breast-Neoplasms

cx-4945 has been researched along with Triple-Negative-Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for cx-4945 and Triple-Negative-Breast-Neoplasms

Article	Year
Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy. Journal of medicinal chemistry, 2021, 12-23, Volume: 64, Issue:24 Bromodomain-containing protein 4 (BRD4) is an attractive epigenetic target in human cancers. Inhibiting the phosphorylation of BRD4 by casein kinase 2 (CK2) is a potential strategy to overcome drug resistance in cancer therapy. The present study describes the synthesis of multiple BRD4-CK2 dual inhibitors based on rational drug design, structure-activity relationship, and Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Casein Kinase II; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mice; Structure-Activity Relationship; Transcription Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2021

Article

Year

Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.

Journal of medicinal chemistry, 2021, 12-23, Volume: 64, Issue:24

Bromodomain-containing protein 4 (BRD4) is an attractive epigenetic target in human cancers. Inhibiting the phosphorylation of BRD4 by casein kinase 2 (CK2) is a potential strategy to overcome drug resistance in cancer therapy. The present study describes the synthesis of multiple BRD4-CK2 dual inhibitors based on rational drug design, structure-activity relationship, and

Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Casein Kinase II; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mice; Structure-Activity Relationship; Transcription Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2021